Multiple lines of neuroscientific evidence have converged on a set of closely related findings: the mammalian brain endogenously synthesizes N,N-dimethyltryptamine (DMT) at neurotransmitter-comparable concentrations (Dean et al., 2019); psychedelic compounds suppress the default mode network (DMN) and dissolve ego boundaries (Carhart-Harris et al., 2012; Tagliazucchi et al., 2016); the brain...
Mammalian brain may contain an endogenous pool of the psychedelic substance N,N-dimethyltryptamine (DMT), which may act as a co-transmitter with serotonin (5-HT). We tested the joint hypotheses. We tested the joint hypotheses that endogenous DMT would accumulate in rat brain after inhibiting monoamine oxidase with pargyline, whereas its acidic metabolite 3-indoleacetic acid (3-IAA) would...
Mammalian brain may contain an endogenous pool of the psychedelic substance N,N-dimethyltryptamine (DMT), which may act as a co-transmitter with serotonin (5-HT). We tested the joint hypotheses. We tested the joint hypotheses that endogenous DMT would accumulate in rat brain after inhibiting monoamine oxidase with pargyline, whereas its acidic metabolite 3-indoleacetic acid (3-IAA) would...
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a serotonin receptor agonist, in clinical development for the treatment of major depression and other psychiatric disorders. A critical safety concern for serotonergic compounds is their potential to induce seizures, as a severe manifestation of serotonin toxicity. The objective of this study was to evaluate the seizure liability of 5-MeO-DMT in a...
Journal of NeurochemistryJanuary 29, 2026Paola Andrea Caro Aponte, Edison Huertas Montoya, Ítalo Odone Mazali et al.
Currently, no effective treatment exists for injuries at the interface between the CNS/PNS, largely due to their complex pathophysiology and the limited efficacy of single-target therapies. To address this challenge, we investigated a novel combinatorial therapeutic strategy integrating surgical VRR with fibrin sealant biopolymer (FSB) and DMT in a rat model of ventral root avulsion VRA. DMT...
Major depressive disorder (MDD) remains a leading cause of disability worldwide, with current treatments limited by delayed onset and low efficacy. The serotonergic psychedelic N,N-dimethyltryptamine (DMT) has shown rapid antidepressant effects in early clinical studies, yet its mechanisms and efficacy remain poorly characterized in established models of depression. Here, we evaluated the...
N,N-dimethyltryptamine (DMT) is a fast-acting psychedelic drug that induces a radical reorganization of conscious contents and brain dynamics. However, our understanding of how brain dynamics support psychedelic-induced conscious states remains unclear. We therefore present a repeated-measures dose-dependent study of the subjective and neural dynamics induced through DMT under naturalistic...
January 8, 2026Michael Esposito, Ana M Ortiz Bernal, Alan K. Davis et al.
preprint
Clinical trials using 5-MeO-DMT to treat various mental health conditions are currently underway, however research on 5-MeO-DMT use in humans is limited. To date, no scoping review of the published, peer-reviewed literature exists. The purpose of the present analysis is to examine the extent, range, and nature of peer-reviewed research on the use of 5-MeO-DMT in humans and, ultimately, to...
El presente trabajo de investigación tuvo como objetivo identificar, analizar, conglomerar y describir los efectos relatados de la experiencia en personas que consumen o han consumido dimetiltriptamina (DMT) en cualquiera de sus métodos de administración, así como examinar su uso potencial como auxiliar terapéutico. Las técnicas de índole metodológica empleadas fueron la investigación...